Skip to main content
Toggle navigation
Login
Search
Home
ICPE 2023 Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
All Days
Fri, Aug 25
Sat, Aug 26
Sun, Aug 27
Poster Schedule
Type here to filter the list
Friday, August 25, 2023
8:00 AM – 6:00 PM
ADT
(001) Association of ticagrelor versus clopidogrel with major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention across categories of liver disease
Favorite
8:00 AM – 6:00 PM
ADT
(002) Use of Bibliometrics and Altmetrics in Research Impact Assessment of the Canadian Network for Observational Drug Effect Studies: Preliminary Observations
Favorite
8:00 AM – 6:00 PM
ADT
(003) What are the main expectations of patients with hemophilia regarding treatment?
Favorite
8:00 AM – 6:00 PM
ADT
(004) Meta-analysis of the effects of dexmedetomidine on perioperative inflammatory response and hemodynamics in children with congenital heart disease
Favorite
8:00 AM – 6:00 PM
ADT
(006) The Global Seroprevalence of Lyme Disease: A Literature Review
Favorite
8:00 AM – 6:00 PM
ADT
(007) Efficacy and Safety of Pyrazobicin by Thermal Infusion in Treatment of Bladder Cancer: A Meta analysis
Favorite
8:00 AM – 6:00 PM
ADT
(008) Real-world antiretroviral treatment use patterns among people living with HIV in the U.S.
Favorite
8:00 AM – 6:00 PM
ADT
(009) Effectiveness of insulin glargine liraglutide injection in the treatment of type 2 diabetes: a systematic review
Favorite
8:00 AM – 6:00 PM
ADT
(010) Association between the Use of Glucagon-like Peptide 1 Agonist and the Risk of Psoriasis in Diabetes Patients Compare to Dipeptidyl Peptidase-4 inhibitors in Taiwan
Favorite
8:00 AM – 6:00 PM
ADT
(011) Efficacy and safety of Pingxiao capsules in combination with chemotherapy in the treatment of gastric cancer: a systematic review
Favorite
8:00 AM – 6:00 PM
ADT
(012) Meta-analysis of the efficacy and safety of ustekinumab in Crohn's disease
Favorite
8:00 AM – 6:00 PM
ADT
(013) Potential Risk Factors for Delirium during Inpatient Rehabilitation: A Matched Case-Control Study
Favorite
8:00 AM – 6:00 PM
ADT
(014) Meta-analysis of postoperative safety of cantharidith preparation combined with chemotherapy in the treatment of breast cancer
Favorite
8:00 AM – 6:00 PM
ADT
(015) Systematic review of traditional Chinese medicine rhubarb administration via nasal jejunal tube in the treatment of severe acute pancreatitis
Favorite
8:00 AM – 6:00 PM
ADT
(016) Efficacy and Safety of Kangai Injection Combined with Platinum-based Chemotherapy for the Treatment of Ovarian Cancer: A Systematic Review and Meta‑analysis
Favorite
8:00 AM – 6:00 PM
ADT
(017) Effectiveness of Aspirin in The Treatment of Preeclampsia and Related Pregnancy Outcomes: A Meta Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(018) Meta-analysis of traditional Chinese medicine for cough
Favorite
8:00 AM – 6:00 PM
ADT
(019) A systematic review of the efficacy and safety of dobutamine in the treatment of sepsis
Favorite
8:00 AM – 6:00 PM
ADT
(020) Systematic evaluation of the efficacy of Shenqi Fuzheng injection combined with CAF chemotherapy in the treatment of breast cancer and the clinical effect of peripheral blood picture
Favorite
8:00 AM – 6:00 PM
ADT
(021) Community Pharmacy Perspectives on Assessing Kidney Function and Medication Dosing for Advanced Chronic Kidney Disease: A Qualitative Study
Favorite
8:00 AM – 6:00 PM
ADT
(022) A systematic review of the safety of crow bile oil emulsion injection combined with GP regimen in the treatment of non-small cell lung cancer
Favorite
8:00 AM – 6:00 PM
ADT
(023) Systematic evaluation and meta-analysis on the treatment of moderate and severe cancer pain in cancer patients with traditional chinese medicine combined with three-step analgesic method
Favorite
8:00 AM – 6:00 PM
ADT
(024) Risk of Pancreatitis with the Use of Glucagon-like peptide 1 (GLP1) agonists: Analyses of the Post-Marketing FDA Adverse Event Reporting System (FAERS) Database
Favorite
8:00 AM – 6:00 PM
ADT
(025) Quantitative benefit-risk assessment of vaccination against COVID-19: a systematic literature review
Favorite
8:00 AM – 6:00 PM
ADT
(026) Effectiveness of additional risk minimisation measures: Improving response rates and validity in surveys
Favorite
8:00 AM – 6:00 PM
ADT
(027) Increased risk of retinal vascular occlusion in patients receiving cataract surgery: causation or biased association?
Favorite
8:00 AM – 6:00 PM
ADT
(028) Non-steroidal anti-inflammatory drug use for migraine and arterial thromboembolic risks: A Danish population-based matched cohort study
Favorite
8:00 AM – 6:00 PM
ADT
(029) Trajectories of EU Paediatric Investigation Plans for Oncology approved since 2007 and Resulting Paediatric Cancer Indications
Favorite
8:00 AM – 6:00 PM
ADT
(030) Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(031) Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(032) Exploitation of data available in open access on the consumption of medication in France: use case on anti-TNF biosimilars market penetration
Favorite
8:00 AM – 6:00 PM
ADT
(034) The Prescription Pattern of Biologics for Crohn’s Disease Patients in Taiwan
Favorite
8:00 AM – 6:00 PM
ADT
(037) Purchases of Biological Medicines by the Ministry of Health During the Approval of Biosimilars in Brazil
Favorite
8:00 AM – 6:00 PM
ADT
(038) Real-world evaluation of the persistence of the most used drug groups in Rheumatoid Arthritis from 2017 to 2021 in the Public Health System, Brazil
Favorite
8:00 AM – 6:00 PM
ADT
(039) Dispensation of Biologic and Non-Biologic Medication in the Brazilian Public Health System
Favorite
8:00 AM – 6:00 PM
ADT
(040) Persistence Associated With The Use Of Biologicals For The Treatment Of Ankylosing Spondylitis In The Brazilian Public Health System
Favorite
8:00 AM – 6:00 PM
ADT
(041) Predictors of effectiveness of biologic Disease-Modifying Antirheumatic Drugs (bDMARD) in the treatment of psoriatic arthritis
Favorite
8:00 AM – 6:00 PM
ADT
(042) Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: systematic review and meta-analysis
Favorite
8:00 AM – 6:00 PM
ADT
(043) Renal Adverse Events in Patients with Diabetic Macular Edema Receiving Intravitreal Vascular Endothelial Growth Factors Inhibitors
Favorite
8:00 AM – 6:00 PM
ADT
(044) The Impact of External Factors on Spontaneous Reporting Practices: A Time Series Analysis of FAERS Data
Favorite
8:00 AM – 6:00 PM
ADT
(045) Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Favorite
8:00 AM – 6:00 PM
ADT
(046) Differences in Time to Onset Between Spontaneous Reports and Cohort Studies: The Case of the COVID-19 Vaccines
Favorite
8:00 AM – 6:00 PM
ADT
(047) Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries
Favorite
8:00 AM – 6:00 PM
ADT
(048) Effectiveness of 2-dose COVID-19 Vaccination Against SARS-CoV-2 Infection and Severe Outcomes in Cancer Patients
Favorite
8:00 AM – 6:00 PM
ADT
(049) The role of comorbidities in the development of AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
Favorite
8:00 AM – 6:00 PM
ADT
(050) The Characteristics of Abnormal Uterine Bleeding Reports Following COVID-19 Vaccination
Favorite
8:00 AM – 6:00 PM
ADT
(051) Background rates of cardiovascular events in patients at high risk of severe COVID-19 before and during the COVID-19 pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(052) Adverse post-vaccination events reported with anti-COVID-19 vaccines in Burkina Faso: analysis of spontaneous reports
Favorite
8:00 AM – 6:00 PM
ADT
(053) COVID 19 vaccine associated thromboembolic events-A VAERS database study
Favorite
8:00 AM – 6:00 PM
ADT
(054) COVID-19-related Pharmacovigilance Surveillance Based On A Spontaneous Reporting Database
Favorite
8:00 AM – 6:00 PM
ADT
(055) Time-to-onset of glomerular diseases following COVID-19 vaccination: a case series analysis
Favorite
8:00 AM – 6:00 PM
ADT
(056) Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya
Favorite
8:00 AM – 6:00 PM
ADT
(057) Assessment of COVID-19 vaccine-related adverse events in VigiAccess
Favorite
8:00 AM – 6:00 PM
ADT
(058) The challenges and lessons learnt from conducting COVID-19 monitoring studies through VAC4EU: coordination and management perspective
Favorite
8:00 AM – 6:00 PM
ADT
(059) Discovering the Risk Factors of the COVID-19 Vaccine-induced Carditis applying the Machine Learning Approach: Based on Real World Data
Favorite
8:00 AM – 6:00 PM
ADT
(060) National U.S. Claims-Based Cohort Study of the Safety of Adenoviral Vector COVID-19 Vaccination during Pregnancy
Favorite
8:00 AM – 6:00 PM
ADT
(061) Assessment of COVID-19 and Mpox Vaccine Data when Supplementing Administrative Claims with Immunization Information System Data
Favorite
8:00 AM – 6:00 PM
ADT
(062) Factors Associated With Influenza and COVID-19 Vaccination in Older Adults
Favorite
8:00 AM – 6:00 PM
ADT
(063) Vaccination Use among Pregnant Women 2016-2022: An Analysis Using Healthcare Claims
Favorite
8:00 AM – 6:00 PM
ADT
(064) Monitoring Results From a Postapproval Safety Study of Pfizer-BioNTech COVID-19 Vaccine in the United States: Vaccine Utilization and Incidence Rates of Myocarditis/Pericarditis
Favorite
8:00 AM – 6:00 PM
ADT
(065) COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network
Favorite
8:00 AM – 6:00 PM
ADT
(066) Multi-regional population-based cohort study for the evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: The VENUS Study
Favorite
8:00 AM – 6:00 PM
ADT
(067) Validation of a Claims-based Algorithm for Myocarditis/Pericarditis using Medical Chart Review
Favorite
8:00 AM – 6:00 PM
ADT
(068) Safety & immUnogenicity of COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED): Preliminary Results of 1031 Patients
Favorite
8:00 AM – 6:00 PM
ADT
(069) Identification and characterization of patients receiving a 1st booster of COVID-19 vaccines in a US administrative database
Favorite
8:00 AM – 6:00 PM
ADT
(070) Medical chart review of selected adverse event of special interest (AESI) to support rapid safety assessment of the Janssen COVID-19 vaccine (JCOVDEN): a validation study using US electronic health records and claims data
Favorite
8:00 AM – 6:00 PM
ADT
(071) Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 Vaccines in Four Large US National Insurers
Favorite
8:00 AM – 6:00 PM
ADT
(072) Waning vaccine response after primary vaccine series: Results from the COVID19 VaccinE Response in Rheumatology patients (COVER) study
Favorite
8:00 AM – 6:00 PM
ADT
(073) Assessment of mortality after mRNA COVID-19 vaccination in Japan: The VENUS Study
Favorite
8:00 AM – 6:00 PM
ADT
(074) Safety of COVID-19 Vaccines Among People With Prior History Of SARS-Cov-2 Infection: Results From the COVID-Vaccine-Monitor Cohort Event Monitoring
Favorite
8:00 AM – 6:00 PM
ADT
(075) The Adverse Events Following COVID-19 Vaccination – A Two-year Surveillance conducted in a sentinel site in south India
Favorite
8:00 AM – 6:00 PM
ADT
(076) Behaviors and associated determinants of COVID-19 vaccine acceptance and advocacy: a nationwide survey of pharmacy professionals using the Theoretical Domains Framework
Favorite
8:00 AM – 6:00 PM
ADT
(077) Updated Real-World Safety of the Pfizer-BioNTech COVID-19 Vaccine in Pregnancy: Data from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry
Favorite
8:00 AM – 6:00 PM
ADT
(078) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data: Methods and Results of the First Study Feasibility Assessment
Favorite
8:00 AM – 6:00 PM
ADT
(079) Vaccines effectiveness against hospitalizations ‘for’ and ‘with’ COVID-19, after clinical histories review
Favorite
8:00 AM – 6:00 PM
ADT
(080) Implementation of childhood immunization registry – a post-pandemic intervention to Track the immunization gaps created during COVID-19
Favorite
8:00 AM – 6:00 PM
ADT
(081) An Analysis Of The Impact Of The COVID-19 Pandemic Outbreak On Incident Patient Diagnoses In Primary Care In England Using An Interrupted Time Series
Favorite
8:00 AM – 6:00 PM
ADT
(082) Visualizing Discrepancies Between a Body of Trials and a Real-World Population: An Example from the COVID-19 Pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(083) Definitions of Long COVID Among Published Research Studies
Favorite
8:00 AM – 6:00 PM
ADT
(084) Real World Effectiveness of Anticoagulation in Hospitalized COVID-19 Patients using High-Resolution EHR Data in the Presence of Time-varying Confounding: Out with the Old, In with the New
Favorite
8:00 AM – 6:00 PM
ADT
(085) Inhaled corticosteroid prescription patterns in UK primary care before and during the COVID-19 pandemic in patients with COPD
Favorite
8:00 AM – 6:00 PM
ADT
(086) Inaccuracy of Using ICD-10-CM Diagnosis Code U07.1 to Identify Outpatients with COVID-19 in US Claims Data
Favorite
8:00 AM – 6:00 PM
ADT
(087) Risk Prediction of Long COVID with Machine Learning in a Real-World Setting
Favorite
8:00 AM – 6:00 PM
ADT
(088) Linking real world data to assess risk of post-acute outcomes following COVID-19 infection in England: the ECHOES national surveillance system
Favorite
8:00 AM – 6:00 PM
ADT
(089) Clinical characteristics and healthcare resource utilization among patients identified with post-acute sequelae of COVID-19 (long-COVID) in US administrative claims data
Favorite
8:00 AM – 6:00 PM
ADT
(090) Validation of severe COVID-19 information recorded in BIFAP
Favorite
8:00 AM – 6:00 PM
ADT
(091) Assessing COVID-19’s impact on condition measurement in claims data
Favorite
8:00 AM – 6:00 PM
ADT
(092) Ursodeoxycholic acid may be a new protective factor for severe COVID-19 outcomes – evidence from a nationwide Swedish register-based cohort study within the SCIFI-PEARL project
Favorite
8:00 AM – 6:00 PM
ADT
(093) Rapid Production of Pharmacoepidemiology Results to Inform Regulatory Decision-making: Lessons Learned from the COVID-19 Pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(094) High dose dexamethasone for COVID-19 not common in a large US hospital network
Favorite
8:00 AM – 6:00 PM
ADT
(095) Pilot Surveillance of Infant Lower Respiratory Tract Infections and Respiratory Syncytial Virus in the United States During the COVID Pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(096) Association of Xuebijing treatment with clinical outcomes in COVID-19 patients: a retrospective cohort study with propensity score matching
Favorite
8:00 AM – 6:00 PM
ADT
(097) The Impact of the COVID-19 Pandemic on the Burden of Opioid Toxicity Deaths Across Canada
Favorite
8:00 AM – 6:00 PM
ADT
(098) COVID-19 Infection and Medicines in Pregnancy in Canada
Favorite
8:00 AM – 6:00 PM
ADT
(099) Association between race and COVID-19 outcomes in the United States (2020-2021)
Favorite
8:00 AM – 6:00 PM
ADT
(100) Timing and Duration of Remdesivir Treatment Among Individuals Hospitalized due to COVID-19 in the Capital Region of Denmark
Favorite
8:00 AM – 6:00 PM
ADT
(101) The impact of prenatal maternal mental health during the COVID-19 pandemic on birth outcomes: A study within the CONCEPTION cohort
Favorite
8:00 AM – 6:00 PM
ADT
(102) Rise of Underscreening of Depression Post COVID-19 in the US
Favorite
8:00 AM – 6:00 PM
ADT
(103) Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19 - An analysis from a population-based cohort within the SCIFI-PEARL project
Favorite
8:00 AM – 6:00 PM
ADT
(104) Validation of COVID-related ICD-10-CM Symptom Codes in Electronic Health Records
Favorite
8:00 AM – 6:00 PM
ADT
(105) Impact of the COVID-19 pandemic on initiation of anti-diabetic drug consumption pattern in Sweden - An interrupted time series study
Favorite
8:00 AM – 6:00 PM
ADT
(106) FACTORS ASSOCIATED WITH SELF-MEDICATION DURING THE COVID-19 PANDEMIC IN CHINCHA – PERU: A CROSS-SECTIONAL STUDY
Favorite
8:00 AM – 6:00 PM
ADT
(107) Impact of the COVID-19 Pandemic on Use of Medication and Healthcare Services Among Individuals with Intellectual and Developmental Disabilities in Ontario, Canada
Favorite
8:00 AM – 6:00 PM
ADT
(108) Impact of COVID-19 Pandemic on Leukotriene Receptor Antagonists Prescribing
Favorite
8:00 AM – 6:00 PM
ADT
(109) Long COVID symptoms following primo- vs reinfection: a multinational cohort analysis of primary care records from Catalonia and the UK
Favorite
8:00 AM – 6:00 PM
ADT
(110) Antibacterial Drug Use Among Hospitalized Patients with COVID-19 During Successive Epidemic Waves in Hong Kong
Favorite
8:00 AM – 6:00 PM
ADT
(111) Utilization of Telemedicine and antibiotic dispensing before and during the COVID-19 pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(112) Postpartum depressive symptoms among Danish new mothers and fathers before and during the COVID-19 pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(113) Clinical and Economic Characteristics of Patients Diagnosed with Long COVID: Early Findings from Real-World Data
Favorite
8:00 AM – 6:00 PM
ADT
(114) Thromboembolism Risk and Management Pattern in Hospitalized COVID-19 Patients: A Single-Center Experience in Ethiopia
Favorite
8:00 AM – 6:00 PM
ADT
(115) Racial and Ethnic Differences in Hospitalized and Critical COVID-19 Treatment, January 2021-April 2022
Favorite
8:00 AM – 6:00 PM
ADT
(116) Rates of Antidepressant, Antiepileptic and Anxiolytic Prescribing Among People Living with Dementia During the COVID-19 Pandemic: A Multinational Interrupted Time-Series Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(117) Disparities in prescriptions medications use by socioeconomic status and geographical location during COVID-19 pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(118) Pediatric and Adolescent Medication Use Before and During COVID-19: A Population-Based Cohort Study in Manitoba, Canada
Favorite
8:00 AM – 6:00 PM
ADT
(119) Establishing and Characterising Large COVID-19 Cohorts After Mapping the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model
Favorite
8:00 AM – 6:00 PM
ADT
(120) Convalescent Plasma Utilization Among Inpatient U.S. Medicare Beneficiaries Ages 65 and Older Diagnosed with COVID-19 During 2020-2021
Favorite
8:00 AM – 6:00 PM
ADT
(121) Characterization of Long COVID among U.S. Medicare Beneficiaries using Claims Data
Favorite
8:00 AM – 6:00 PM
ADT
(122) Changes in systemic cancer therapy in Australia during the later COVID-19 pandemic (2020 – 2022): a population-based study
Favorite
8:00 AM – 6:00 PM
ADT
(123) Risk of Post-Acute Sequelae of COVID (PASC) Among Patients With Type 2 Diabetes Mellitus on Various Anti-Diabetic Drug Classes
Favorite
8:00 AM – 6:00 PM
ADT
(124) The Missing Claimants of the Pandemic: Who Went Without Claims in Canada During the First Two Years of the COVID-19 Pandemic and what Does it Mean for Public and Private drug plans?
Favorite
8:00 AM – 6:00 PM
ADT
(125) Impact of COVID-19 on Hormonal Contraceptive Dispensing in Kentucky: An Interrupted Time Series Design
Favorite
8:00 AM – 6:00 PM
ADT
(126) Pregnancy during a pandemic: pregnancy occurrence and outcomes during the SARS-CoV-2 pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(127) Characteristics of Pregnant People Treated With Sotrovimab for COVID-19 from the COVID-19 International Drug Pregnancy Registry (COVID-PR)
Favorite
8:00 AM – 6:00 PM
ADT
(128) Identifying fit-for-purpose existing data sources for COVID-19 pre-exposure prophylaxis in pregnancy
Favorite
8:00 AM – 6:00 PM
ADT
(129) Characteristics of data collected in MID-NET®
Favorite
8:00 AM – 6:00 PM
ADT
(130) Baseline characteristics of patients with chronic kidney disease and type 2 diabetes (CKD-T2D) initiating anti-hyperglycemic medication: differences before and during the outbreak of COVID-19 in US and UK
Favorite
8:00 AM – 6:00 PM
ADT
(131) Depression among Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients before and during the COVID-19 Pandemic Era: a US-claims Based Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(132) Efficacy and safety of Remdesivir in COVID-19 patients: An overview of meta-Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(133) Immunosuppressive therapy and covid-19-related hospitalization in solid organ transplant recipients: a French nationwide cohort study
Favorite
8:00 AM – 6:00 PM
ADT
(134) Medication Delivery Incidents Reported in Community Pharmacies in Canada: A pre- and post- pandemic analysis
Favorite
8:00 AM – 6:00 PM
ADT
(136) Quality of Adverse Events Reporting in Clinical Trials of COVID-19 Drugs: a systematic review
Favorite
8:00 AM – 6:00 PM
ADT
(137) The Impact of the COVID lock-down on transitions from a once-monthly parenteral therapy for osteoporosis in the U.S. Medicare program
Favorite
8:00 AM – 6:00 PM
ADT
(138) Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting
Favorite
8:00 AM – 6:00 PM
ADT
(139) Background Rates of Pediatric-Onset Type I Diabetes Before and During the COVID-19 Pandemic
Favorite
8:00 AM – 6:00 PM
ADT
(140) Systemic Steroids and its Combination with Remdesivir in Hospitalized COVID-19 Patients: A Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
ADT
(141) Using administrative data to understand substance misuse patterns in understudied populations: A child welfare sample
Favorite
8:00 AM – 6:00 PM
ADT
(142) Focus on types of risk minimization measures for carditis, associated with COVID-19 vaccines- FAERS Database Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(143) The Impact of COVID-19 on Mental Health of Health Sciences Students in India: A Survey-Based Study
Favorite
8:00 AM – 6:00 PM
ADT
(145) Identification of Gastrointestinal Perforations in Patients with Inflammatory Bowel Diseases: Challenges and Opportunities in Administrative Claims Data
Favorite
8:00 AM – 6:00 PM
ADT
(146) Considerations in estimating complete prevalence of cancers using Surveillance, Epidemiology, and End Results (SEER) databases using marginal zone lymphoma (MZL) and acute myeloid leukemia (AML) as case examples
Favorite
8:00 AM – 6:00 PM
ADT
(147) Trends in severe COPD exacerbations and mortality following the introduction of ultra-long-acting bronchodilators: an interrupted time-series study between 2007 and 2018 in Quebec, Canada
Favorite
8:00 AM – 6:00 PM
ADT
(148) Understanding the journey and complications in patients with type 2 diabetes from the US and the UK: an OMOP-based data network analysis
Favorite
8:00 AM – 6:00 PM
ADT
(149) Type 2 Diabetes, the Epidemic: Trends in Incidence and Prevalence, 2004-2020
Favorite
8:00 AM – 6:00 PM
ADT
(150) To Link or Not to Link: Insights from comparison of CPRD Aurum and CPRD GOLD with linked Hospital Episode Statistics (HES) APC, HES Outpatient, and Cancer Registry data
Favorite
8:00 AM – 6:00 PM
ADT
(151) Development and validation of a risk prediction model for estimating the disease progression in patients with NAFLD
Favorite
8:00 AM – 6:00 PM
ADT
(152) Clinically Relevant Real-World Predictors of Hospitalization in Patients with Major Depressive Disorder
Favorite
8:00 AM – 6:00 PM
ADT
(153) Evaluating uptake of lung cancer screening in the United States (US) from 2017-2021
Favorite
8:00 AM – 6:00 PM
ADT
(154) Epidemiology of Wilson Disease in France: a Nationwide Claims-based Study
Favorite
8:00 AM – 6:00 PM
ADT
(155) Replicating a US-claims cardiovascular use case in Japanese databases: opportunities and challenges
Favorite
8:00 AM – 6:00 PM
ADT
(156) Incidence and prevalence of common cancers in the United Kingdom from 2000-2019: a population-based cohort study
Favorite
8:00 AM – 6:00 PM
ADT
(157) Prevalence and characteristics of patients with advanced/metastatic NSCLC with HER2 mutations
Favorite
8:00 AM – 6:00 PM
ADT
(158) Medication Treatment for Depression and Reduced Productivity Among Adults with Major Depressive Disorder in the US
Favorite
8:00 AM – 6:00 PM
ADT
(159) Use of US Health Insurance Claims Data to Determine Cause of Death
Favorite
8:00 AM – 6:00 PM
ADT
(160) Trajectories of Pharmacological Therapies for Treatment-Resistant Depression: A Large Longitudinal Study based on Commercial Claims Data Linked to Electronic Medical Records
Favorite
8:00 AM – 6:00 PM
ADT
(161) Cannabis Use Disorder Symptom Profiles among Individuals Reporting Past-year Cannabis Use in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(162) Estimation of global age-specific prevalence of essential tremor by literature review of population-based studies
Favorite
8:00 AM – 6:00 PM
ADT
(163) Type 2 Diabetes in France and the UK: Assessing Prevalence, Patient Management Practices, and Clinical Outcomes using Two Large Databases
Favorite
8:00 AM – 6:00 PM
ADT
(164) The Risk of Cardiovascular Events in Patients with Resistant Hypertension
Favorite
8:00 AM – 6:00 PM
ADT
(165) Incidence of adrenal insufficiency in patients with solid malignancies treated with immune checkpoint inhibitors
Favorite
8:00 AM – 6:00 PM
ADT
(166) Real-world Treatment Patterns in Recurrent or Advanced Endometrial Cancer Patients on First-line Systemic Therapy in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(167) Heart failure burden in patients with incident CKD in the US: a multi-database FOUNTAIN analysis
Favorite
8:00 AM – 6:00 PM
ADT
(168) Improving Incident Hypertension Identification Using Real World Data
Favorite
8:00 AM – 6:00 PM
ADT
(169) Treatment with antidiabetics in patients with T2D and moderate to severe CKD: a multi-database FOUNTAIN analysis
Favorite
8:00 AM – 6:00 PM
ADT
(170) The Clinical Presentation of and Mortality in Stroke Patients Using Glucocorticoids
Favorite
8:00 AM – 6:00 PM
ADT
(171) Factors affecting readmission in patients with surgical site infection: A graphical and prediction model-based approach
Favorite
8:00 AM – 6:00 PM
ADT
(172) Lifestyle factors and risk of prostate cancer in men with benign prostatic hyperplasia: A cohort study from UK Biobank
Favorite
8:00 AM – 6:00 PM
ADT
(173) Treatment-resistant depression and risk of autoimmune diseases: evidence from a nested case-control study
Favorite
8:00 AM – 6:00 PM
ADT
(174) Factors associated with diabetic cataract:a population-based nested case-control study in korea
Favorite
8:00 AM – 6:00 PM
ADT
(175) Prevalence of Risk Categories of Chronic Kidney Disease with and without Type 2 Diabetes
Favorite
8:00 AM – 6:00 PM
ADT
(176) Long-term metabolic effect of common drugs used for chronic disease. A Mexican cohort study
Favorite
8:00 AM – 6:00 PM
ADT
(178) Characteristics of Patients with Resistant Hypertension and Non-resistant Hypertension Identified Using Real-world Data
Favorite
8:00 AM – 6:00 PM
ADT
(179) Assessment of the Use of Real-World Data to Support a Study in Patients with Advanced Cancer and Cachexia
Favorite
8:00 AM – 6:00 PM
ADT
(180) Utilizing Real World Data from a National Database of Living Donor Kidney Transplants to identify Targeted Subgroups for Planned Intervention Trials to prolong graft survival
Favorite
8:00 AM – 6:00 PM
ADT
(181) Annual Trends in the Prevalence of HIV-Lipodystrophy and the use of Stavudine and Zidovudine Among Patients with HIV in the United States (US)
Favorite
8:00 AM – 6:00 PM
ADT
(182) Dynamic Change in HBsAg in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Analogues in China
Favorite
8:00 AM – 6:00 PM
ADT
(183) Assessment of the Disease Pattern and Drug Utilization among the Neuro ICU Patients
Favorite
8:00 AM – 6:00 PM
ADT
(184) Using linkage between routinely and prospectively collected data to improve disease definitions
Favorite
8:00 AM – 6:00 PM
ADT
(185) Exploring the heterogeneity of results in multi-database studies: an example using the EXACOS-CV programme
Favorite
8:00 AM – 6:00 PM
ADT
(186) FOUNTAIN: a modular research platform for Integrated Real-World Evidence Generation
Favorite
8:00 AM – 6:00 PM
ADT
(187) Effect of Metformin on the Risk of Depression: A Systematic Review and Meta-Regression of Observational Studies
Favorite
8:00 AM – 6:00 PM
ADT
(188) Risk factor of death after the first suicidal behavior in patients with depressive disorder
Favorite
8:00 AM – 6:00 PM
ADT
(189) Bariatric surgery and all-cause mortality: a methodological review of studies using a non-surgical comparator
Favorite
8:00 AM – 6:00 PM
ADT
(190) Quantitative Bias Analysis Methods for Summary Level Epidemiologic Data: A Systematic Review
Favorite
8:00 AM – 6:00 PM
ADT
(191) Using real-world general practitioner data to study the diagnosis and management of dementia: rationale and design
Favorite
8:00 AM – 6:00 PM
ADT
(192) Suspected Falsified Pill Involvement in U.S. Poison Centers Abuse Cases 2019-2022
Favorite
8:00 AM – 6:00 PM
ADT
(193) Use of a Clustering Algorithm for Treatment Sequences (TAK®) as a Pre-processing Step to Explanatory and Predictive Models
Favorite
8:00 AM – 6:00 PM
ADT
(194) Impact of minimum enrollment period requirements on disease prevalence estimates derived from claims data
Favorite
8:00 AM – 6:00 PM
ADT
(195) Curation of a research-ready evidence hub: A development framework for robust, fit-for-purpose data
Favorite
8:00 AM – 6:00 PM
ADT
(196) Risk of Psychotropic Treatment Change after Cancer Treatment Initiation Among Cancer Survivors with Mental Health Comorbidity
Favorite
8:00 AM – 6:00 PM
ADT
(198) Factors associated with Type2 Diabetes Mellitus development based on Korean National Health Insurance Sharing Service data
Favorite
8:00 AM – 6:00 PM
ADT
(199) Knowledge, attitudes and practices towards prevention of hepatitis B infection among students of Gulu University, Uganda
Favorite
8:00 AM – 6:00 PM
ADT
(200) Assessment of Potential Risk Factors and Biochemical Predictors for the Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Favorite
8:00 AM – 6:00 PM
ADT
(201) Initiation of psychotropic medications after hospital discharge in survivors of critical illness, a retrospective cohort study (2012-2019)
Favorite
8:00 AM – 6:00 PM
ADT
(202) Mapping of ICD-9 codes to ICD-10 for commonly assessed comorbidities in claims database studies
Favorite
8:00 AM – 6:00 PM
ADT
(203) Low-dose aspirin prescriptions and risk of breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up
Favorite
8:00 AM – 6:00 PM
ADT
(204) Long-term Clinical Outcomes in Patients with IgA Nephropathy: Retrospective Cohort Study using a US Electronic Medical Database
Favorite
8:00 AM – 6:00 PM
ADT
(205) Effects of sodium-glucose cotransporter 2 inhibitors on the risk of atrial fibrillation in older adults with type 2 diabetes
Favorite
8:00 AM – 6:00 PM
ADT
(206) Relative effectiveness of direct-acting oral anticoagulants by dose in patients with atrial fibrillation: A network meta-analysis
Favorite
8:00 AM – 6:00 PM
ADT
(207) Risk of Suicidal Behavior after Benztropine Initiation
Favorite
8:00 AM – 6:00 PM
ADT
(208) Oral Anticoagulants and Risk of Type 2 Diabetes among Adults with Atrial Fibrillation in the United Kingdom
Favorite
8:00 AM – 6:00 PM
ADT
(209) Thiazolidinediones and rheumatoid arthritis in patients with type 2 diabetes mellitus: A retrospective cohort study
Favorite
8:00 AM – 6:00 PM
ADT
(210) Trends in the use of raloxifene among older adults, 1999 - 2022
Favorite
8:00 AM – 6:00 PM
ADT
(211) Pain control associated with opioid and gabapentinoid prescription after elective knee replacement
Favorite
8:00 AM – 6:00 PM
ADT
(212) Cardiovascular safety of non-steroidal anti-inflammatory drug use for gout: A Danish nationwide case-crossover study
Favorite
8:00 AM – 6:00 PM
ADT
(213) Marijuana Use and the Risk of Incident Venous Thromboembolism in People with HIV
Favorite
8:00 AM – 6:00 PM
ADT
(214) Metformin and Risk of Dementia: Real World Evidence
Favorite
8:00 AM – 6:00 PM
ADT
(215) Vitamin D Serum Levels, Supplementation and Suicidal Behavior in Veterans
Favorite
8:00 AM – 6:00 PM
ADT
(216) The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, meta-analysis, and network meta-analysis
Favorite
8:00 AM – 6:00 PM
ADT
(217) A retrospective cohort study to evaluate the impact of chemotherapy dose delays on survival in breast cancer patients in England
Favorite
8:00 AM – 6:00 PM
ADT
(218) Prevalence of Comorbidities and Multimorbidity Among Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Observational Study in a Large US Commercially Insured and Medicare Advantage Population
Favorite
8:00 AM – 6:00 PM
ADT
(219) Discharging postoperative patients with an opioid prescription may result in greater reliance on opioid itself and increased healthcare expenditure and mortality
Favorite
8:00 AM – 6:00 PM
ADT
(220) Survival Benefits of Adjuvant Oral Endocrine Therapy among Female Medicare Beneficiaries with Early-stage Breast Cancer
Favorite
8:00 AM – 6:00 PM
ADT
(221) Incidence of Active Tuberculosis According to Latent Tuberculosis Infection Treatment Before Targeted Therapy in Patients with Rheumatoid Arthritis
Favorite
8:00 AM – 6:00 PM
ADT
(222) Weight Loss Associated with Semaglutide Treatment in People with HIV
Favorite
8:00 AM – 6:00 PM
ADT
(223) Comparing the Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI in Qatar: A Retrospective Cohort Study Using Real-World Data
Favorite
8:00 AM – 6:00 PM
ADT
(225) Associations between antihypertensive medication use and kidney cancer incidence using the Korean nationwide insurance database
Favorite
8:00 AM – 6:00 PM
ADT
(226) The Influence of Timing of Cholecystectomy on the Incidence of Post-ERCP Pancreatitis: A Systematic Review & Meta-Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(227) Systematic review of externally controlled (EC) trials, data used in them, and their role in regulatory decision-making
Favorite
8:00 AM – 6:00 PM
ADT
(228) Self-care Practices Intervention among Adults with Uncontrolled Hypertension in Ibadan, Nigeria
Favorite
8:00 AM – 6:00 PM
ADT
(229) A Comprehensive Systematic Review and Meta-Analysis of the Efficacy and Safety of Bexagliflozin in Patients with Type 2 Diabetes Mellitus
Favorite
8:00 AM – 6:00 PM
ADT
(231) Lessons learned for data harmonisation and integration from secondary use of randomised controlled trial (RCT) and real-world data in the context of a study to evaluate external comparator arm study results versus RCT results
Favorite
8:00 AM – 6:00 PM
ADT
(232) Disease relapse, adverse events and all-cause mortality associated with the use of long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia: a self-controlled case series study
Favorite
8:00 AM – 6:00 PM
ADT
(233) Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Favorite
8:00 AM – 6:00 PM
ADT
(234) Protective effects of medications on cardiovascular events in systemic lupus erythematosus in real-life: a systematic new-user cohort study
Favorite
8:00 AM – 6:00 PM
ADT
(235) A population-based evaluation of the real-world effectiveness of nirmatrelvir/ritonavir for reducing hospitalization and mortality from COVID-19
Favorite
8:00 AM – 6:00 PM
ADT
(236) Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized with COVID-19: A Target Trial Emulation Study
Favorite
8:00 AM – 6:00 PM
ADT
(237) Paxlovid and COVID-19 related hospitalization or death in clinically extremely vulnerable patients
Favorite
8:00 AM – 6:00 PM
ADT
(238) The Prevalence of Aortic Stenosis and Aortic Valve Replacement in the United States: A Retrospective Descriptive Claims Study
Favorite
8:00 AM – 6:00 PM
ADT
(239) Risk of Carpal Tunnel Syndrome among Patients with Osteoarthritis
Favorite
8:00 AM – 6:00 PM
ADT
(240) Clinical and Economic Burden Associated with Prolonged Air Leaks Among Patients Undergoing Thoracic Resection: A Retrospective Database Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(241) Characteristics and Outcomes of Patients Undergoing Kidney Ablation Via the NEUWAVE Microwave Ablation System from an Innovative Linkage of Device-Generated and Electronic Health Record Data
Favorite
8:00 AM – 6:00 PM
ADT
(242) Analysis of SARS-CoV-2 Testing Patterns Post-PAXLOVID TM Prescription Orders and Analysis of Patients with Multiple PAXLOVID Prescription Orders
Favorite
8:00 AM – 6:00 PM
ADT
(243) Influence of Cancer Stage at Diagnosis on Lung Cancer Prognosis of Targetable Molecular Patient Subgroups
Favorite
8:00 AM – 6:00 PM
ADT
(244) Survey of Infection Control Practices at Ambulatory Surgery Centers (ASCs) and Outpatient Hospitals that Perform Gastrointestinal Endoscopic Procedures in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(245) Efficacy of Hippocampal Avoidance Whole Brain Radiation Therapy in Preventing Neurocognitive Dysfunction Induced by Radiation Therapy in Patients with Brain Metastases: A Systematic Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
ADT
(246) Artificial intelligence in medical devices: an era of advancement? Or Safety concern?
Favorite
8:00 AM – 6:00 PM
ADT
(247) Day-to-Day Variability in Sleep Parameters and Sleep Impairment Among Adolescents With Mood Disorders Treated With Antidepressants
Favorite
8:00 AM – 6:00 PM
ADT
(248) A safety Review of Clinical Adverse Events Associated with Cardiovascular Medical Devices under Materiovigilance
Favorite
8:00 AM – 6:00 PM
ADT
(249) Bariatric Surgery Utilization Trends in the United States: 2012–2021
Favorite
8:00 AM – 6:00 PM
ADT
(250) Self-testing to increase HIV testing among men who have sex with men: results from an integrative literature review
Favorite
8:00 AM – 6:00 PM
ADT
(251) Adverse events related to medical devices in the Social Security - EsSalud in Peru (2018-2021): a descriptive analysis of a surveillance system
Favorite
8:00 AM – 6:00 PM
ADT
(252) Percutaneous Left Atrial Appendage Occlusion and Risk of Stroke, Hospitalized Bleeding and Death in Medicare Beneficiaries with Atrial Fibrillation
Favorite
8:00 AM – 6:00 PM
ADT
(253) Using Linked Registry–Electronic Health Records to Examine Amputations following Peripheral Vascular Intervention
Favorite
8:00 AM – 6:00 PM
ADT
(254) Reverse Causation Bias: A Simulation Study Comparing First- and Second-Line Treatments With an Overlap of Symptoms Between Treatment Indication and Studied Outcome
Favorite
8:00 AM – 6:00 PM
ADT
(255) Evaluating bias from index date selection methods under varying assumptions in external control analyses using real-world comparators
Favorite
8:00 AM – 6:00 PM
ADT
(256) Leveraging External Validation Data to Address Misclassification: The Challenge of Transporting Misclassification Probabilities
Favorite
8:00 AM – 6:00 PM
ADT
(257) A Framework for Determining Sample Size for External Control Arms
Favorite
8:00 AM – 6:00 PM
ADT
(258) Examining the External Comparator Arm Design: A Simulation Study
Favorite
8:00 AM – 6:00 PM
ADT
(259) High-dose vs. standard-dose influenza vaccine and cardiopulmonary hospitalization or mortality: emulating the INVESTED trial using insurance claims data
Favorite
8:00 AM – 6:00 PM
ADT
(260) Risk of cardiovascular death and hospitalization for heart failure with sacubitril/valsartan vs. enalapril in clinical practice: application of outcome models developed with clinical trial data from PARADIGM-HF
Favorite
8:00 AM – 6:00 PM
ADT
(261) Development and Validation of a Claims-based Algorithm for Moderate-to-Severe Atopic Dermatitis
Favorite
8:00 AM – 6:00 PM
ADT
(262) How To Use High Dimensional Approach To Assist Non-Active Comparator Selection In The Retrospective Study: A Case Study For WATCHMAN Device
Favorite
8:00 AM – 6:00 PM
ADT
(263) Using claims data to identify the exact indication of use for biological drugs approved for Immune-Mediated Inflammatory Diseases: The VALORE project experience
Favorite
8:00 AM – 6:00 PM
ADT
(264) How can advanced analytics and innovative data visualizations improve the understanding of cancer healthcare pathways trajectories?
Favorite
8:00 AM – 6:00 PM
ADT
(265) Quality of Electronic Health Records: Variability of Missing Data for Social Determinants of Health by Healthcare Systems
Favorite
8:00 AM – 6:00 PM
ADT
(266) Development and Validation of a Tool to Assess Perceptions, Perspectives, Practice and Satisfaction in Patients Taking Oral anticoagulants
Favorite
8:00 AM – 6:00 PM
ADT
(267) Impact of using limited duration prevalence (LDP) vs. complete prevalence (CP) on racial/ethnic distributions derived from the Surveillance, Epidemiology, and End Results (SEER) database
Favorite
8:00 AM – 6:00 PM
ADT
(268) Evaluation of Commonly Used Real World Data Sources Submitted to ASCO Journals: Initial Steps Toward Furthering Transparent Reporting
Favorite
8:00 AM – 6:00 PM
ADT
(269) Measuring Inhaled Medication Compliance: A Study Using a Novel Developed Questionnaire
Favorite
8:00 AM – 6:00 PM
ADT
(270) Validation of Real-World Case Definitions for COVID-19 Diagnosis and Severe COVID-19 Illness Among Patients Infected with SARS-CoV-2: Translation of Clinical Trial Definitions to Real-World Settings
Favorite
8:00 AM – 6:00 PM
ADT
(271) Validation of a disability proxy for multiple sclerosis using digitized health records from the FlywheelMS cohort
Favorite
8:00 AM – 6:00 PM
ADT
(272) Development and Validation of Claims-based Algorithms for Conjunctivitis and Keratitis
Favorite
8:00 AM – 6:00 PM
ADT
(273) Comparing the performance of nested case-control and case-crossover study designs for assessing adverse outcomes of concomitant drug use: a simulation study
Favorite
8:00 AM – 6:00 PM
ADT
(274) Adapting the prevalent new-user study design to evaluate the effects of drug discontinuation: A simulation study
Favorite
8:00 AM – 6:00 PM
ADT
(275) Scalable natural language processing of electronic health records to supplement large-scale covariate adjustment in pharmacoepidemiologic studies
Favorite
8:00 AM – 6:00 PM
ADT
(276) Addressing bias due to socioeconomic status in the comparative effectiveness of sodium-glucose co-transporter 2 inhibitors vs. sulfonylureas in patients with type 2 diabetes
Favorite
8:00 AM – 6:00 PM
ADT
(277) Assessing joint covariate balance in matched observational studies with high-dimensional categorical variables
Favorite
8:00 AM – 6:00 PM
ADT
(278) Negative control outcome adjustment to tackle unmeasured confounding: A case study of oral quinolone and tendon rupture
Favorite
8:00 AM – 6:00 PM
ADT
(279) Time-varying propensity score matching as a method to balance baseline covariates and calendar time effects in a real-world effectiveness analysis
Favorite
8:00 AM – 6:00 PM
ADT
(A01) Disparities in Guideline-Recommended Pharmacotherapy for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Sex: A Nationally Representative Cross-Sectional Analysis of Adults in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(A02) Ethnic differences in the indirect impacts of the COVID-19 pandemic on hospitalisations for non-COVID conditions in England: An observational cohort study using OpenSAFELY
Favorite
8:00 AM – 6:00 PM
ADT
(A03) Ethnicity differences in risk of cardiovascular events in COVID-19: an England-wide population analysis
Favorite
8:00 AM – 6:00 PM
ADT
(A04) Representation of patients of minority race and ethnicity in real-world databases and tumor registries of patients with breast cancer
Favorite
8:00 AM – 6:00 PM
ADT
(A05) Social Determinants of Health and Disparities in T2DM Severity in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(A06) The Impact of Contextual-Level Social Determinants of Health on Heart Failure Readmission and Mortality in Patients Hospitalized for Heart Failure
Favorite
8:00 AM – 6:00 PM
ADT
(A07) The Use of Computational Phenotypes Within Electronic Healthcare Data to Identify Transgender People: A Narrative Review
Favorite
8:00 AM – 6:00 PM
ADT
(A08) Using Real-World Data to Support Clinical Trial Diversity and Inclusion Strategies: A Case Study of Cancer of the Cervix
Favorite
8:00 AM – 6:00 PM
ADT
(A09) Clinical validation studies for SARS-CoV-2 diagnostic tests in a real-world setting
Favorite
8:00 AM – 6:00 PM
ADT
(A10) Continuous Glucose Monitoring in Diabetes Patients with Cognitive Impairment
Favorite
8:00 AM – 6:00 PM
ADT
(A11) COVID-RED: A randomized trial demonstrating earlier COVID-19 remote detection using wearable technology and artificial intelligence
Favorite
8:00 AM – 6:00 PM
ADT
(A13) Robot-assisted Surgery and Racial and Ethnic Disparities in Post-prostatectomy Outcomes among Prostate Cancer Patients
Favorite
8:00 AM – 6:00 PM
ADT
(A14) Systematic Review and Meta-analysis of Clinical Outcomes of Bone Grafting/Reconstruction Following Segmental Long Bone Defects Treated by Induced Membrane Technique
Favorite
8:00 AM – 6:00 PM
ADT
(A15) Temporal Trends in Using Catheter Ablation as First-Line Therapy in Patients Diagnosed with Paroxysmal Atrial Fibrillation in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(A16) Trends in the Cost of Total Knee Arthroplasty — a US Hospital Database Analysis, 2000 – 2021
Favorite
8:00 AM – 6:00 PM
ADT
(A17) Antidepressant Utilization Before and After Initiation of Prenatal Care Among Commercially Insured Pregnant Women in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(A18) Maternal Exposure of Benzodiazepine Receptor Agonists and Increased Risk of Neurodevelopmental Disorders in Offspring in Taiwan
Favorite
8:00 AM – 6:00 PM
ADT
(A19) Maternal Prescribed Opioid Analgesic Use During Pregnancy and Associations with Neurodevelopmental Disorders in Offspring
Favorite
8:00 AM – 6:00 PM
ADT
(A20) Social and Demographic Disparities in the Adherence to Antihypertensive Medication During Pregnancy
Favorite
8:00 AM – 6:00 PM
ADT
(A21) Topical azole treatments during pregnancy: Are there risks for the pregnant mother and the fetus? A comparative study in the EFEMERIS database
Favorite
8:00 AM – 6:00 PM
ADT
(A22) Utilization of antihypertensives before, during, and after pregnancy
Favorite
8:00 AM – 6:00 PM
ADT
(A23) Utilization patterns of Antidepressants in pregnant women: An interrupted time series analysis
Favorite
8:00 AM – 6:00 PM
ADT
(A24) Validation study of an ASA prophylaxis variable for preeclampsia prevention
Favorite
8:00 AM – 6:00 PM
ADT
(A25) An Observational Post Approval Safety Study of Etanercept and Methotrexate in Treatment of Juvenile Idiopathic Arthritis (JIA) using the German Biologics JIA Registry (BIKER)
Favorite
8:00 AM – 6:00 PM
ADT
(A26) Antiepileptic Drug Use in Children Beyond Epilepsy: A Population-Based Longitudinal Study
Favorite
8:00 AM – 6:00 PM
ADT
(A27) Incidence of COVID-19 disease severity in a cohort of 4.4 million Italian and Spanish children from 6 healthcare databases
Favorite
8:00 AM – 6:00 PM
ADT
(A28) Metrics of Antibiotic Use in Neonatal Intensive Care Units
Favorite
8:00 AM – 6:00 PM
ADT
(A29) Natural History of RSV Infection in Outpatient Pediatric Patients in the United States
Favorite
8:00 AM – 6:00 PM
ADT
(A30) Overview of Global Real World Data Sources for Pediatric Pharmacoepidemiologic Research
Favorite
8:00 AM – 6:00 PM
ADT
(A31) Population-Based Incidence of Influenza-Associated Serious Neuropsychiatric Events
Favorite
8:00 AM – 6:00 PM
ADT
(A32) Utilization of beta-blockers among the pediatric population in the United States: a study in the FDA’s Sentinel System from 2008 to 2022
Favorite
8:00 AM – 6:00 PM
ADT
(A33) A Retrospective Cohort Study Using Administrative Claims to Compare the Incidence of Eosinophilic Granulomatosis with Polyangiitis in Patients with and without Asthma, Stratified by Asthma Severity
Favorite
8:00 AM – 6:00 PM
ADT
(A34) Analgesics Utilization in Danish Cystic Fibrosis Patients
Favorite
8:00 AM – 6:00 PM
ADT
(A35) Characteristics, Disease Burden, and Preliminary Outcomes of Patients with Myasthenia Gravis in Real-World Treatment Settings Across the United States
Favorite
8:00 AM – 6:00 PM
ADT
(A36) Diagnosed Prevalence of Hypophosphatasia in the United States: a Real World Analysis of Electronic Health Records
Favorite
8:00 AM – 6:00 PM
ADT
(A38) Epidemiology of rare kidney diseases in the United Kingdom using a large rare renal registry
Favorite
8:00 AM – 6:00 PM
ADT
(A39) Federated Hospital Electronic Health Record Networks for Trial Feasibility Assessments in Rare Diseases: A Pilot Study in Neurofibromatosis Type 1
Favorite
8:00 AM – 6:00 PM
ADT
(A40) Identifying Generalized Pustular Psoriasis Flares Using Natural Language Processing of Unstructured Clinical Notes and Structured Procedure Codes
Favorite
8:00 AM – 6:00 PM
ADT
(A41) Cardiovascular Risk and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors: A Nationwide Comparative Effectiveness Research Study
Favorite
8:00 AM – 6:00 PM
ADT
(A42) Case studies of FDA recently approved product applications using real-world evidence - What are the attributes of studies that support effectiveness determinations?
Favorite
8:00 AM – 6:00 PM
ADT
(A43) Decreased Venous Thromboembolic Risk of Estradiol Valerate/Dienogest COCs Compared to First-line COCs Containing Ethinyl Estradiol/Levonorgestrel: Pooled Analysis in a Large Real-World User Population
Favorite
8:00 AM – 6:00 PM
ADT
(A44) Lessons Learned from the Development of Machine Learning Models to Estimate Validated Measures Using Real-World Data for Four Chronic Conditions
Favorite
8:00 AM – 6:00 PM
ADT
(A45) Machine Learning to Predict Successful Treatment of Atrial Fibrillation by Medical Devices Using Digital Data Linked to EHR Data
Favorite
8:00 AM – 6:00 PM
ADT
(A46) Progression to ESRD Among White, Black and Hispanic Diabetic Kidney Disease Patients: Real-World Evidence from Multiple Linked Claims Databases
Favorite
8:00 AM – 6:00 PM
ADT
(A47) Use and contribution of registries in registry-based randomized clinical trials: a review
Favorite
8:00 AM – 6:00 PM
ADT
(A48) Use of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification in Europe: a DARWIN-EU® multinational network cohort study (EUPAS103381)
Favorite
8:00 AM – 6:00 PM
ADT
(A49) Carditis risk following covid-19 vaccination with mRNA (BNT162b2) or inactivated (CoronaVac): a self-controlled cases series and a case-control study
Favorite
8:00 AM – 6:00 PM
ADT
(A50) Characterization of U.S. Adults Aged 18–64 Years Vaccinated Against Mpox within the Food and Drug Administration Biologics Effectiveness and Safety (BEST) Initiative
Favorite
8:00 AM – 6:00 PM
ADT
(A51) Evaluation of the risk of potential adverse events following bivalent COVID-19 vaccines in Veteran patients
Favorite
8:00 AM – 6:00 PM
ADT
(A52) Post-marketing surveillance of human papillomavirus (HPV)-related high-grade cervical disease in a cohort of Chinese women who received the 9-valent HPV vaccine
Favorite
8:00 AM – 6:00 PM
ADT
(A53) Safety monitoring of COVID-19 vaccines in multiple European countries: initial results from the COVID-19 Vaccine Monitor (CVM)
Favorite
8:00 AM – 6:00 PM
ADT
(A54) The effect of sex on the incidence, latency, duration and burden of adverse events following influenza vaccination
Favorite
8:00 AM – 6:00 PM
ADT
(A55) The importance of contextualising overall measures of COVID-19 vaccine effectiveness: the COVIDRIVE-AstraZeneca experience
Favorite
8:00 AM – 6:00 PM
ADT
(A56) Vaccine patterns among older adults diagnosed with Guillain-Barré Syndrome and matched counterparts with Medicare insurance, 2006-2019
Favorite
